Long-term of Remote Ischemic Preconditioning and Mindfulness in Patients With Hypertension

Hypertension is a major risk factor for cardiovascular disease. Remote ischemic conditioning (RIC) and mindfulness-based interventions are non-pharmacological approaches that may help reduce blood pressure through different physiological mechanisms. However, evidence regarding their long-term effects and potential combined benefits remains limited.

This multicenter, randomized, sham-controlled clinical trial evaluated the effects of RIC, mindfulness-based intervention, and their combination on home blood pressure in patients with hypertension. A total of 600 participants were randomly assigned to four groups in a 2×2 factorial design. The interventions were administered twice daily for 12 months. The primary objective was to assess changes in home systolic blood pressure after 12 months of intervention. Secondary objectives included evaluating diastolic blood pressure, the time course of blood pressure changes, treatment response, and safety.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This was a multicenter, randomized, sham-controlled, 2×2 factorial clinical trial conducted at five hospitals in China. A total of 600 patients with essential hypertension were enrolled between September 2023 and August 2024 and randomly assigned in a 1:1:1:1 ratio to four intervention groups:

  1. Control group: sham remote ischemic conditioning (RIC) combined with nature-sound audio.
  2. RIC group: active RIC combined with nature-sound audio.
  3. Mindfulness group: sham RIC combined with guided mindfulness intervention.
  4. Combination group: active RIC combined with guided mindfulness intervention.

Active RIC consisted of three cycles of upper-arm cuff inflation for 6 minutes followed by deflation for 4 minutes, with a total session duration of 30 minutes. Inflation pressure was individualized according to baseline systolic blood pressure using predefined pressure increments. Sham RIC followed the same inflation-deflation schedule with a cuff pressure of 60 mmHg.

The mindfulness intervention consisted of standardized audio-guided mindfulness practice delivered simultaneously with the cuff intervention. The control audio consisted of natural sounds, such as ocean waves, flowing water, and birdsong, without hypertension education or mindfulness instructions. Both interventions were administered twice daily for 12 months.

Home blood pressure was measured repeatedly throughout the study using an automated monitoring system. The primary outcome was the change in pre-intervention home systolic blood pressure from baseline to 12 months. Additional assessments included diastolic blood pressure, longitudinal blood pressure trajectories, blood pressure control and response rates, immediate blood pressure responses, treatment adherence, and adverse events.

Selected circulating biomarkers were also measured in a subset of participants for mechanistic investigations.

The study was designed to assess the independent and combined effects of RIC and mindfulness-based intervention on long-term blood pressure control.

Study Type

Interventional

Enrollment (Actual)

600

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Luoyang, China, 471000
        • The First Affiliated Hospital of Henan University of Science and Technology
    • Henan
      • Anyang, Henan, China, 455000
        • Anyang District Hospital
      • Kaifeng, Henan, China, 475000
        • Huaihe Hospital of Henan University
      • Shangqiu, Henan, China, 476600
        • Yongcheng Central Hospital
      • Zhengzhou, Henan, China, 450008
        • Fuwai central China Cardiovascular hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults aged 18-80 years.
  • Diagnosis of essential hypertension according to established clinical guidelines, with a mean screening home systolic blood pressure (SBP) of 135-179 mmHg and a mean home diastolic blood pressure (DBP) below 105 mmHg.
  • Participants who were either untreated or receiving antihypertensive medication with inadequately controlled blood pressure. For participants receiving antihypertensive medication, drug classes and doses had to remain stable for at least 4 weeks before enrollment, with no planned active adjustment during the study.
  • Completion of at least 2 weeks of twice-daily home blood pressure monitoring during screening, with the mean home SBP remaining within 135-179 mmHg before randomization.
  • Ability and willingness to perform twice-daily home blood pressure monitoring and complete the 12-month intervention and follow-up.
  • Provision of written informed consent.

Exclusion Criteria:

  • Secondary hypertension of any cause or incomplete screening for secondary causes of hypertension.
  • Cardiovascular or cerebrovascular events within 6 months before enrollment.
  • Clinically significant arrhythmias, including atrial fibrillation or frequent ventricular premature beats, that could interfere with automated blood pressure measurement.
  • Peripheral vascular disease, severe upper-limb vascular insufficiency, or conditions precluding safe cuff inflation, including an arteriovenous fistula in the measurement arm, lymphedema, skin lesions, or upper-limb surgery within the preceding 3 months.
  • Orthostatic hypotension, defined as a systolic blood pressure decrease of at least 20 mmHg on standing or symptomatic orthostatic hypotension.
  • Inter-arm systolic blood pressure difference greater than 15 mmHg.
  • Severe target-organ damage, including estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m², left ventricular ejection fraction (LVEF) below 40%, or New York Heart Association (NYHA) functional class III-IV.
  • Poorly controlled diabetes mellitus (HbA1c ≥9.0%) or established diabetic autonomic neuropathy.
  • Pregnancy, planned pregnancy, or lactation.
  • Participation in another interventional clinical trial within 30 days before enrollment.
  • Inability to comply with the study protocol because of cognitive impairment, severe psychiatric disorders, or logistical difficulties with follow-up.
  • Confirmed mean screening home DBP ≥105 mmHg on repeat measurement.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: CRIC+MFT

CRIC :Twice daily for 12 months using an automated cuff device. Each 30-minute session consisted of 3 cycles of 6 min inflation (pressure individualized: resting SBP-based increments of +40/+30/+20 mmHg depending on baseline SBP level) followed by 4 min deflation (0 mmHg).

MFT:Twice daily guided audio sessions (synchronized with CRIC timing) emphasizing focused attention on breath and bodily sensations to foster mindful awareness.

Remote Ischemic Conditioning (CRIC): Twice daily for 12 months using an automated cuff device. Each 30-minute session consisted of 3 cycles of 6 min inflation (pressure individualized: resting SBP-based increments of +40/+30/+20 mmHg depending on baseline SBP level) followed by 4 min deflation (0 mmHg).

Mindfulness-based intervention (MFT) consisted of standardized audio-guided mindfulness practice focusing on breath awareness, bodily sensations, and nonjudgmental present-moment awareness. Each session lasted approximately 30 minutes and was delivered twice daily for 12 months, synchronized with the CRIC or sham CRIC procedure.

Experimental: sham CRIC+MFT

Sham CRIC: Identical schedule and device; each cycle used fixed 5 min inflation at 60 mmHg (non-ischemic) followed by 5 min deflation.

MFT: Twice daily guided audio sessions (synchronized with CRIC timing) emphasizing focused attention on breath and bodily sensations to foster mindful awareness.

Mindfulness-based intervention (MFT) consisted of standardized audio-guided mindfulness practice focusing on breath awareness, bodily sensations, and nonjudgmental present-moment awareness. Each session lasted approximately 30 minutes and was delivered twice daily for 12 months, synchronized with the CRIC or sham CRIC procedure.

Mindfulness-based intervention (MFT) consisted of standardized audio-guided mindfulness practice focusing on breath awareness, bodily sensations, and nonjudgmental present-moment awareness. Each session lasted approximately 30 minutes and was delivered twice daily for 12 months, synchronized with the CRIC or sham CRIC procedure.

Experimental: CRIC+sham MFT

CRIC :Twice daily for 12 months using an automated cuff device. Each 30-minute session consisted of 3 cycles of 6 min inflation (pressure individualized: resting SBP-based increments of +40/+30/+20 mmHg depending on baseline SBP level) followed by 4 min deflation (0 mmHg).

Sham MFT: Twice daily equivalent-duration audio of looped neutral nature sounds (ocean waves, flowing water, birdsong) without mindfulness instructions.

Remote Ischemic Conditioning (CRIC): Twice daily for 12 months using an automated cuff device. Each 30-minute session consisted of 3 cycles of 6 min inflation (pressure individualized: resting SBP-based increments of +40/+30/+20 mmHg depending on baseline SBP level) followed by 4 min deflation (0 mmHg).

The control audio consisted of standardized recordings of natural sounds, including ocean waves, flowing water, and birdsong, without mindfulness instructions, breathing exercises, or hypertension-related health education. Each audio session lasted approximately 30 minutes and was delivered twice daily for 12 months, synchronized with the CRIC or sham CRIC procedure.

Placebo Comparator: Sham CRIC+Sham MFT

Sham CRIC: Identical schedule and device; each cycle used fixed 5 min inflation at 60 mmHg (non-ischemic) followed by 5 min deflation.

Sham MFT: Twice daily equivalent-duration audio of looped neutral nature sounds (ocean waves, flowing water, birdsong) without mindfulness instructions.

Mindfulness-based intervention (MFT) consisted of standardized audio-guided mindfulness practice focusing on breath awareness, bodily sensations, and nonjudgmental present-moment awareness. Each session lasted approximately 30 minutes and was delivered twice daily for 12 months, synchronized with the CRIC or sham CRIC procedure.

The control audio consisted of standardized recordings of natural sounds, including ocean waves, flowing water, and birdsong, without mindfulness instructions, breathing exercises, or hypertension-related health education. Each audio session lasted approximately 30 minutes and was delivered twice daily for 12 months, synchronized with the CRIC or sham CRIC procedure.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in Home Systolic Blood Pressure at 12 Months
Time Frame: Baseline (screening days -7 to -1) and Month 12 (days 335-364 after randomization)

Change in mean pre-intervention home systolic blood pressure (SBP) from screening baseline to the 12-month endpoint window. Home blood pressure was measured twice daily using an automated device. Three measurements were obtained before each intervention session; the first reading was excluded, and the mean of the remaining two readings was used. The 12-month endpoint was calculated as the mean of valid pre-intervention SBP measurements during days 335-364 after randomization. Participants with at least 20 valid measurement sessions during this window were included in the primary endpoint analysis. The outcome was expressed in mmHg.

Baseline (screening days -7 to -1) and Month 12 (days 335-364 after randomization)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change From Baseline in Home Diastolic Blood Pressure at 12 Months
Time Frame: Baseline (screening days -7 to -1) and Month 12 (days 335-364)

Change in mean pre-intervention home diastolic blood pressure (DBP) from screening baseline to the 12-month endpoint window. Home blood pressure was measured twice daily using an automated device. Three measurements were obtained before each intervention session; the first reading was discarded, and the mean of the remaining two readings was used. The 12-month endpoint was calculated as the mean of valid pre-intervention DBP measurements during days 335-364 after randomization. Changes were expressed in mmHg.

Baseline (screening days -7 to -1) and Month 12 (days 335-364)
Change From Baseline in Home Systolic Blood Pressure at Months 1, 3, 6, and 9
Time Frame: Baseline and Days 30, 90, 180, and 270 after randomization

Changes in mean pre-intervention home systolic blood pressure (SBP) from screening baseline at multiple follow-up time points. Home SBP was measured twice daily using an automated device, with the mean of the second and third pre-intervention readings used for each session. Window-mean SBP values were calculated around days 30, 90, 180, and 270 after randomization to characterize the longitudinal blood pressure response to the assigned interventions. Changes were expressed in mmHg.

Baseline and Days 30, 90, 180, and 270 after randomization
Proportion of Participants Achieving a Systolic Blood Pressure Reduction of at Least 5 mmHg
Time Frame: Baseline and Month 12 (days 335-364)

Proportion of participants achieving a reduction of at least 5 mmHg in mean pre-intervention home systolic blood pressure from screening baseline to the 12-month endpoint window (days 335-364 after randomization). The response rate was calculated as the number of participants meeting this threshold divided by the number of participants with evaluable endpoint data, expressed as a percentage.

Baseline and Month 12 (days 335-364)
Proportion of Participants Achieving Home Blood Pressure Control Below 135/85 mmHg
Time Frame: Month 12 (days 335-364)

Proportion of participants achieving home blood pressure control, defined as a mean pre-intervention home systolic blood pressure below 135 mmHg and a mean pre-intervention home diastolic blood pressure below 85 mmHg during the 12-month endpoint window (days 335-364 after randomization). Blood pressure control rates were expressed as percentages among participants with evaluable endpoint data.

Month 12 (days 335-364)
Proportion of Participants Achieving Home Blood Pressure Control Below 140/90 mmHg
Time Frame: Month 12 (days 335-364)

Proportion of participants achieving home blood pressure control using a less stringent threshold, defined as a mean pre-intervention home systolic blood pressure below 140 mmHg and a mean pre-intervention home diastolic blood pressure below 90 mmHg during the 12-month endpoint window (days 335-364 after randomization). Blood pressure control rates were expressed as percentages among participants with evaluable endpoint data.

Month 12 (days 335-364)
Within-Session Change in Home Systolic Blood Pressure
Time Frame: Throughout the 12-month intervention period

The immediate blood pressure response was assessed as the difference between post-intervention and pre-intervention home systolic blood pressure within each treatment session. Three consecutive blood pressure measurements were obtained before and after each session, with the first reading excluded and the mean of the remaining two readings used for each time point. The participant-level mean of post-intervention minus pre-intervention SBP differences was calculated across available sessions. Between-group comparisons relative to the double-sham control group were used to estimate the net immediate intervention effect, expressed in mmHg.

Throughout the 12-month intervention period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Chair: Muwei Li, MD, Chinese Academy of Medical Sciences, Fuwai Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2023

Primary Completion (Actual)

August 31, 2025

Study Completion (Actual)

January 1, 2026

Study Registration Dates

First Submitted

February 10, 2021

First Submitted That Met QC Criteria

February 10, 2021

First Posted (Actual)

February 15, 2021

Study Record Updates

Last Update Posted (Actual)

November 10, 2026

Last Update Submitted That Met QC Criteria

November 5, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HenanICE202103

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

IPD can be obtained from the researcher upon reasonable request

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.